Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D00VFH
|
|||
| Former ID |
DIB006905
|
|||
| Drug Name |
PXS-25
|
|||
| Indication | Fibrosis [ICD-11: GA14-GC01; ICD-10: L90.5; ICD-9: 709.2] | Phase 1 | [1] | |
| Company |
Pharmaxis Ltd
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | CI Man-6-P receptor (IGF2R) | Target Info | Inhibitor | [1] |
| KEGG Pathway | Lysosome | |||
| Panther Pathway | Apoptosis signaling pathway | |||
| Insulin/IGF pathway-mitogen activated protein kinase kinase/MAP kinase cascade | ||||
| Insulin/IGF pathway-protein kinase B signaling cascade | ||||
| Reactome | Golgi Associated Vesicle Biogenesis | |||
| WikiPathways | miR-targeted genes in muscle cell - TarBase | |||
| miR-targeted genes in lymphocytes - TarBase | ||||
| miR-targeted genes in leukocytes - TarBase | ||||
| miR-targeted genes in epithelium - TarBase | ||||
| miR-targeted genes in adipocytes - TarBase | ||||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | Cation-independent mannose 6-phosphate receptor inhibitor (PXS25) inhibits fibrosis in human proximal tubular cells by inhibiting conversion of latent to active TGF-beta1. Am J Physiol Renal Physiol.2011 Jul;301(1):F84-93. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.